5-[(2,3-Dihydro-benzofuran-5-ylmethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester | 554443-08-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 英文名称: 5-[(2,3-Dihydro-benzofuran-5-ylmethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 5-(2,3-dihydro-1-benzofuran-5-ylmethylcarbamoyl)-4-methyl-2-(octylcarbamoylamino)thiophene-3-carboxylate
• CAS: 554443-08-2
• 化学式: C₂₉H₄₁N₃O₅S
• 分子量: 543.728
• InChiKey: BKUQKXUMBDKGKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  38
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  134
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-Dibutylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester 、 4-methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester 、 二正丁胺 以 hexanes 、 乙酸乙酯 为溶剂， 以afforded 56.9 mg of a solid (45%) after by column chromatography (8:2; hexanes:EtOAc)的产率得到5-[(2,3-Dihydro-benzofuran-5-ylmethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Pancreatic lipase inhibitor compounds, their synthesis and use

  摘要：

  该发明涉及具有结构的化合物：1其中X是O，S，CH2或NR5; Y是O或S; R1是H，取代或未取代的C1-C15烷基，C1-C8烷基芳基，-C（O）OR4，-C（O）NR4R5，-CR6R6'OR4，-CR6R6'OC（O）R4，-CR6R6'OC（O）NHR7，-C（O）NR10R11，-C（O）NR8R9NR8R9，-N（R5）C（O）NHR5或CH2R4; R2是取代或未取代的直链C1-C30烷基或支链C3-C30烷基，芳基，烷基芳基，芳基烷基，杂环芳基烷基或环烷基; R3是H或取代或未取代的C1-C6烷基或C3-C10环烷基; R4是H或取代或未取代的直链或支链C6-C30烷基，芳基，-CH2-芳基，芳基-C1-C15烷基，杂环芳基-C1-C15烷基或C3-C10环烷基; R5是H或取代或未取代的直链或支链C6-C30烷基，芳基C1-C30烷基，杂环芳基烷基或环烷基; R6和R6'各自独立地是H，取代或未取代的C1-C6烷基，二烷基或C3-C10环烷基，或者一起形成一个3-7成员环系统; R7是H或取代或未取代的C1-C12烷基或C3-C10环烷基; R8和R9各自独立地是H，取代或未取代的C1-C6烷基，C1-C6烷氧基，C1-C6烷基芳基或NR8R9一起形成取代的哌嗪或哌啶环或二氢-1H-异喹啉环系统的取代物，或其特定对映体，或其特定互变异构体，或其药学上可接受的盐，并且通过给予该发明化合物的治疗有效量来治疗糖尿病或肥胖症的方法。

  公开号：

  US20030195199A1

文献信息

• PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE
  申请人：OSI Pharmaceuticals, Inc.

  公开号：EP1467978A1

  公开（公告）日：2004-10-20
• EP1467978A4
  申请人：——

  公开号：EP1467978A4

  公开（公告）日：2005-11-02
• US7064122B2
  申请人：——

  公开号：US7064122B2

  公开（公告）日：2006-06-20
• [EN] PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE<br/>[FR] COMPOSES INHIBITEURS DE LA LIPASE PANCREATIQUE, LEUR SYNTHESE ET LEUR UTILISATION
  申请人：OSI PHARM INC

  公开号：WO2003053944A1

  公开（公告）日：2003-07-03

  The subject invention features compounds having the structure:, wherein X is O, S, CH2 or NR5; Y is O or S; R1 is H, substituted or unsubstituted C1­C15 alkyl, C1-C8 alkylaryl, -C(O)OR4, -C(O)NR4R5, -CR6R6'OR4,-CR6R6'OC(O)R4, - CR6R6'OC(O)NHR7, -C(O)NR1oR11, -C(O)NR8R9 NR8R9, -N(R5)C(O)NHR5, or CH2R4; R2 is a substituted or unsubstituted, straight chain C1-C30 alkyl or branched C3 C30 alkyl, aryl, alkylaryl, arylalkyl, heteroarylalkyl or cycloalkyl; R3 is H or substituted or unsubstituted C1-C6 alkyl or C3-C10 cycloalkyl; R4 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl, -CH2-aryl, aryl -C1-C15 alkyl, heteroaryl-C1-C15alkyl or C3-C10 cycloalkyl; R5 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl C1-C30alkyl, heteroarylalkyl or cycloalkyl; R6 and R6' are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyl or C3-C10 cycloalkyl or together form a 3-7 membered ring system; R7 is H or substituted or unsubstituted C1-C12 alkyl or C3-C10 cycloalkyl; R8 and R9 are each independently H, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylaryl, or NR8R9 together form a substituted piperazine or piperidine ring or a dihydro-1H-isoquinoline ring system, or a specific enantiomer thereof, or a specific tautomer, or a pharmaceutically acceptable salt thereof and a method for treating diabetes or obesity by administering a therapeutically effective amount of the compounds of the invention.